Adheren is a biotechnology company focusing on cancer immunotherapy. We have developed our core technology platform, antibody cell conjugation (ACC™), to attach antibodies directly to immune cells, such as T cells. Using this methodology, we have developed an anti-cancer T cell therapy, called ACE-T (Antibody Conjugated Effector T cells). ACE-T has been validated both in vitro and in vivo, presenting promising treatment possibilities in a variety of cancer types. We are currently validating ACE-T technology in human clinical trials. Relative to other cell-based immunotherapy approaches, ACE-T technology requires no genetic engineering of T cells and has a substantially improved dose-titration capability. ACE-T approach is readily compatible with any developed and future antibodies.